A study identifies clinical characteristics and predictors of psoriatic arthritis in patients with juvenile idiopathic ...
Across 2024, top immunology news focused on ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis, ...
Long-term treatment with guselkumab is associated with sustained improvements in joint/skin symptoms and disease activity among patients with active PsA.
In the study, there was a question of whether the imaging made a real difference in the diagnosis of psoriatic arthritis, and we found it didn’t make a huge difference. It didn’t uncover a ...
Adult clinical trials found that Tremfya could treat plaque psoriasis by 16 weeks. Follow-up analysis found that roughly 23% ...
The US Food and Drug Administration (FDA) has approved Steqeyma (ustekinumab-stba), a biosimilar to Johnson & Johnson’s ...
The Waterloo Road actor has been nothing but open and honest about his struggles with arthritis since his diagnosis last year ...
Delayed diagnosis is a widely recognised problem in psoriatic arthritis (PsA) and is directly related to poorer functional ...
Introduction: Anti-Rheumatics Market , which encompass a range of conditions affecting the joints, bones, muscles, and ...
In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on MoonLake Immunotherapeutics (MLTX – Research Report), ...
House: Johnson & Johnson has announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback